
The Algorithmic Franchise: How AI-Driven CRISPR is Rewriting the Biotech Salary Cap
Vertex and NeuraCode's NC-ALZ Phase 3 success triggers a 42% stock surge and a DOJ antitrust probe, highlighting the deep structural friction between ...
Read Full Story →





